|
|
|
|
|
|
|
|
Long-term survival in patients with clear cell adenocarcinoma of ovary treated with irinotecan hydrochloride plus cisplatin therapy as first-line chemotherapy
Article first published online: 28 MAY 2012
DOI: 10.1111/j.1447-0756.2012.01884.x
© 2012 The Authors. Journal of Obstetrics and Gynaecology Research © 2012 Japan Society of Obstetrics and Gynecology
Issue
Journal of Obstetrics and Gynaecology Research
Abstract
Aim:
Several previous reports showed that irinotecan hydrochloride plus
cisplatin (CPT-P) was a candidate first-line chemotherapy regimen for
clear cell adenocarcinoma of the ovary (CCC). However, long-term
survival in CCC patients treated with CPT-P as first-line chemotherapy
remains to be determined. The aim of the present study was to evaluate
the long-term results of CPT-P as first-line chemotherapy for CCC.
Material and Methods: We performed a retrospective review of 31 patients with CCC who were treated with CPT-P between 1996 and 2004.
Results:
The median follow-up period was 91 months.........
Conclusion:
The long-term results suggest CPT-P as a candidate in first-line
chemotherapy for CCC in not only stage I, but also in optimally debulked
stage II-IV patients with pT1/pT2 disease.
Good but need more info.You can also view about this journal in our site i.e.,http://www.omicsonline.org/gynecologyhome.php for more information.
ReplyDelete